Literature DB >> 30266714

FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.

Viviana Cremasco1, Jillian L Astarita2, Angelo L Grauel2, Shilpa Keerthivasan3, Kenzie MacIsaac4, Matthew C Woodruff5,6, Michael Wu2, Lotte Spel2, Stephen Santoro3, Zohreh Amoozgar2, Tyler Laszewski4, Sara Cruz Migoni7, Konstantin Knoblich7,8, Anne L Fletcher7,8, Martin LaFleur2, Kai W Wucherpfennig2, Ellen Pure9, Glenn Dranoff4, Michael C Carroll5,10, Shannon J Turley1,11.   

Abstract

Cancer-associated fibroblasts (CAFs) are generally associated with poor clinical outcome. CAFs support tumor growth in a variety of ways and can suppress antitumor immunity and response to immunotherapy. However, a precise understanding of CAF contributions to tumor growth and therapeutic response is lacking. Discrepancies in this field of study may stem from heterogeneity in the composition and function of fibroblasts in the tumor microenvironment. Furthermore, it remains unclear whether CAFs directly interact with and suppress T cells. Here, mouse and human breast tumors were used to examine stromal cells expressing fibroblast activation protein (FAP), a surface marker for CAFs. Two discrete populations of FAP+ mesenchymal cells were identified on the basis of podoplanin (PDPN) expression: a FAP+PDPN+ population of CAFs and a FAP+PDPN- population of cancer-associated pericytes (CAPs). Although both subsets expressed extracellular matrix molecules, the CAF transcriptome was enriched in genes associated with TGFβ signaling and fibrosis compared with CAPs. In addition, CAFs were enriched at the outer edge of the tumor, in close contact with T cells, whereas CAPs were localized around vessels. Finally, FAP+PDPN+ CAFs suppressed the proliferation of T cells in a nitric oxide-dependent manner, whereas FAP+PDPN- pericytes were not immunosuppressive. Collectively, these findings demonstrate that breast tumors contain multiple populations of FAP-expressing stromal cells of dichotomous function, phenotype, and location. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266714      PMCID: PMC6597261          DOI: 10.1158/2326-6066.CIR-18-0098

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  58 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

Authors:  Katie M Leick; Anthony B Rodriguez; Marit M Melssen; Mouadh Benamar; Robin S Lindsay; Rebeka Eki; Kang-Ping Du; Mahmut Parlak; Tarek Abbas; Victor H Engelhard; Craig L Slingluff
Journal:  Ann Surg       Date:  2019-10       Impact factor: 12.969

Review 3.  Antitumour immunity regulated by aberrant ERBB family signalling.

Authors:  Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

4.  Prognostic Value of Podoplanin in Various Tumors.

Authors:  Xiaohang Wang; Xueying Wang; Vladmir Carvalho; Qianqian Wang; Tingting Li; Jinbang Wang; Yang Chen; Chengming Ni; Subo Liu; Jiaxin Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade.

Authors:  Alexandra Avgustinova; Liam Jenkins; Ute Jungwirth; Marjan Iravani; Adam Mills; Syed Haider; James Harper; Clare M Isacke
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

6.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors:  Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

7.  Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer.

Authors:  Freja Albjerg Venning; Kamilla Westarp Zornhagen; Lena Wullkopf; Jonas Sjölund; Carmen Rodriguez-Cupello; Pontus Kjellman; Mikkel Morsing; Morteza Chalabi Hajkarim; Kyoung Jae Won; Janine Terra Erler; Chris Denis Madsen
Journal:  J Exp Clin Cancer Res       Date:  2021-05-20

Review 8.  Leveraging microenvironmental synthetic lethalities to treat cancer.

Authors:  Kevin J Metcalf; Alaa Alazzeh; Zena Werb; Valerie M Weaver
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

9.  Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Authors:  W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

10.  T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer.

Authors:  Richard A O'Connor; Vishwani Chauhan; Layla Mathieson; Helen Titmarsh; Lilian Koppensteiner; Irene Young; Guilia Tagliavini; David A Dorward; Sandrine Prost; Kevin Dhaliwal; William A Wallace; Ahsan R Akram
Journal:  Oncoimmunology       Date:  2021-07-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.